Mitigating subtherapeutic cabozantinib exposure after prior mitotane therapy in adrenocortical carcinoma: Pharmacological boosting with cobicistat. [PDF]
Br J Clin PharmacolMitotane is an adrenolytic drug with cytotoxic effects, registered for the treatment of advanced adrenocortical carcinoma (ACC), a rare but aggressive tumour type with a poor prognosis despite treatment. Recently, the oral multi‐kinase inhibitor cabozantinib has shown promising results as a potential second‐line treatment option.
van Ton AMP +4 more
europepmc +2 more sources
Editorial Comments to Impact of Adjuvant Radiotherapy and Mitotane on Survival in Localized Adrenocortical Carcinoma: A Retrospective Cohort Study. [PDF]
Int J UrolInternational Journal of Urology, Volume 33, Issue 1, January 2026.
Morozumi K.
europepmc +2 more sources
EDP-mitotane in children: reassuring evidence of reversible side-effects and neurotoxicity
Discover Oncology, 2022 Adrenocortical carcinoma affects one in 5 million children each year. Since prognosis for children older than 4 years is limited, clinicians often choose aggressive treatment with etoposide, doxorubicin, cisplatin (EDP) and mitotane after resection ...
Rebecca V. Steenaard +4 more
doaj +1 more source
An Excellent Clinical and Radiological Response Pattern to Pembrolizumab in a Patient With Metastatic Adrenocortical Carcinoma and Lynch Syndrome. [PDF]
IJU Case RepABSTRACT Introduction The prognosis of unresectable metastatic adrenocortical carcinoma is very poor. We report a case of Lynch syndrome accompanying metastatic adrenocortical carcinoma treated with pembrolizumab. Case Presentation A 73‐year‐old woman was diagnosed with left adrenocortical carcinoma and multiple lung, liver, and lymph node metastases ...
Shimozawa Y +9 more
europepmc +2 more sources
Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
Endocrine Oncology, 2023 Background: This study examined the magnitude of changes and the time required to observe maximal changes in LDL-c, HDL-c, triglycerides (Tg) and non-HDL-c after the introduction of mitotane.
Nadia Gagnon +7 more
doaj +1 more source
Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma
Cells, 2020 Adrenocortical carcinoma (ACC) is a rare cancer with poor prognosis. Mitotane, the standard treatment for ACC, impairs adrenocortical steroid biosynthesis and cholesterol metabolism.
Antonina Germano +10 more
doaj +1 more source
Estrogen-Like Effect of Mitotane Explained by Its Agonist Activity on Estrogen Receptor-α
Biomedicines, 2021 Mitotane is the cornerstone of medical treatment of adrenocortical carcinoma. Estrogenic-like side effects frequently occur in patients, and previous studies explored the chemical nature of the interaction between estrogen receptor-α (ER-α) and toxic ...
Elisa Rossini +9 more
doaj +1 more source
Embolization in an adrenocortical carcinoma as palliative therapy [PDF]
, 1999 Background: With an annual incidence of 0.2% of new cases per 100,000 inhabitants, adrenocortical carcinoma is rare. In advanced tumor only palliative treatment modalities are practicable. Because of scarcity of the tumor, standard treatment has not been
Braunschweig, R. +5 more
core +1 more source
Methylation status of Vitamin D receptor gene promoter in benign and malignant adrenal tumors [PDF]
, 2015 We previously showed a decreased expression of vitamin D receptor (VDR) mRNA/protein in a small group of adrenocortical carcinoma (ACC) tissues, suggesting the loss of a protective role of VDR against malignant cell growth in this cancer type ...
Cappellesso, Rocco +7 more
core +4 more sources
Life, 2021 (1) Background: In clinical settings, data regarding sex are rarely investigated. In women, factors such as body size and composition, hormonal variations, metabolism, and access to care systems and therapy could strongly influence the pharmacological ...
Sarah Allegra +7 more
doaj +1 more source